Details for New Drug Application (NDA): 020757
✉ Email this page to a colleague
The generic ingredient in AVAPRO is irbesartan. There are thirty-eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the irbesartan profile page.
Summary for 020757
Tradename: | AVAPRO |
Applicant: | Sanofi Aventis Us |
Ingredient: | irbesartan |
Patents: | 0 |
Pharmacology for NDA: 020757
Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Suppliers and Packaging for NDA: 020757
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
AVAPRO | irbesartan | TABLET;ORAL | 020757 | NDA | Sanofi-Aventis U.S. LLC | 0024-5850 | 0024-5850-90 | 90 TABLET, FILM COATED in 1 BOTTLE (0024-5850-90) |
AVAPRO | irbesartan | TABLET;ORAL | 020757 | NDA | Sanofi-Aventis U.S. LLC | 0024-5851 | 0024-5851-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0024-5851-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 75MG | ||||
Approval Date: | Sep 30, 1997 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
Approval Date: | Sep 30, 1997 | TE: | AB | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
Approval Date: | Sep 30, 1997 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020757
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AVAPRO | irbesartan | TABLET;ORAL | 020757-003 | Sep 30, 1997 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | AVAPRO | irbesartan | TABLET;ORAL | 020757-001 | Sep 30, 1997 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | AVAPRO | irbesartan | TABLET;ORAL | 020757-003 | Sep 30, 1997 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription